Oxford Nanopore Technologies (ONT) investor relations material

Platform and technology

• Direct electrical sensing reads native DNA, RNA and protein without copying or fragmenting molecules, capturing long-read and short-read information plus molecular modifications.

• Platform reads 100% of the genome versus ~92% for short-read systems; MinION offers portable sequencing, while PromethION scales to ~60 genomes per week on P24.

Clinical adoption

• Clinical grew ~35% YoY in H1 2026 and represents 15% of revenue; management sees potential for 20%-30% of revenue by 2030.

• Infectious disease, rare disease and oncology are the main adoption areas; infectious disease workflows can return results in four hours to inform therapy.

• In leukemia, one run can consolidate eight pathology tests; cited lab costs fall from ~$2,000 to ~$500.

• NHS respiratory metagenomics is rolling out; Natera's MyOme selected the platform for rare disease, with reimbursement helping support wider uptake.

• IVD collaborations with Danaher, bioMérieux and others could support broader clinical adoption over time.

Rare disease evidence

• Genetic Alliance RISE participation aims to build globally recognized real-world evidence, demonstrate clinical utility and encourage broader physician adoption.

• Management characterized the initiative as a long-tail investment intended to support a next wave of growth, rather than deliver a year-one return.